An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
KalVista Pharmaceuticals (NASDAQ: KALV) showcased significant advancements at the KININ2022 conference, presenting promising preclinical data on oral Factor XIIa inhibitors, which block the kallikrein kinin system (KKS) in disease models. CEO Andrew Crockett highlighted these inhibitors as potential treatments for hereditary angioedema (HAE). KalVista also shared data on sebetralstat, an oral therapy for acute HAE attacks, currently in Phase 3 KONFIDENT trial. The company aims to improve patient outcomes in KKS-related diseases with its innovative therapies.
Positive
Presentation of preclinical data for oral Factor XIIa inhibitors showing effectiveness in blocking KKS activation.
Potential therapeutic opportunities identified for oral FXIIa inhibitors in treating HAE and other diseases.
Ongoing Phase 3 KONFIDENT clinical trial for sebetralstat, targeting acute HAE attacks.
Negative
None.
– First preclinical data presented for structurally diverse oral Factor XIIa inhibitors -
– Additional Sebetralstat data also presented -
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented data for its oral Factor XIIa (FXIIa) and plasma kallikrein (PKa) inhibitor programs at the KININ2022 conference in Annecy, France. Presentations for oral FXIIa inhibitors showed that the compounds block the initiation and amplification of the kallikrein kinin system (KKS) in preclinical models. Of note, small molecule FXIIa inhibitors were shown to suppress FXII zymogen enzyme activity, which has been recently implicated as a distinct initiator of KKS activation, and thus may contribute to disease.
“The oral FXIIa inhibitors we are evaluating show great promise by blocking the earliest steps of kallikrein kinin system activation,” said Andrew Crockett, Chief Executive Officer of KalVista. “The discovery of potent, selective, and orally available FXIIa inhibitors may provide novel therapeutic opportunities to treat HAE and other KKS-mediated diseases.”
The following posters were presented at KININ2022:
Oral factor XIIa inhibition blocks angiotensin converting enzyme inhibitor induced angioedema in mouse. Clermont AC, Murugesan N, Feener EP Link here
Oral FXIIa inhibitor KV998086 suppresses FXII zymogen mediated Kallikrein Kinin System activation. Murugesan N, Lee DK, Duckworth EJ, Clermont AC, Hampton SL, Feener EP Link here
Oral sebetralstat (KVD900) provides rapid inhibition of the kallikrein kinin system in patients with HAE. Duckworth EJ, Lee DK, Murugesan N, Rushbrooke L, Hampton SL, Smith M, Yea C, Audhya P, Feener EP Link here
The following presentations occurred at KININ2022:
“Kallikrein Kinin System in Disease.” Keynote address, Dr. Edward Feener, Chief Scientific Officer
“From Bench to Clinic: Oral Inhibitors of the Kallikrein-Kinin System for the Treatment of HAE.” Lunchtime symposium, Ms Sally Hampton, VP Research and Dr. Chris Yea, Chief Development Officer.
About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for acute HAE attacks and has initiated the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
For more information about KalVista, please visit www.kalvista.com.
For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.
For more information on the KVD824 HAE prophylaxis Phase 2 KOMPLETE study, please visit www.kompletestudy.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT and Phase 2 KOMPLETE clinical trials, and to obtain regulatory approvals for sebetralstat, KVD824 and other candidates in development, the ability of sebetralstat, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
What is the significance of KalVista's oral Factor XIIa inhibitors presented at KININ2022?
KalVista's oral Factor XIIa inhibitors show promise in inhibiting the kallikrein kinin system, which may provide new therapeutic options for hereditary angioedema (HAE).
What trials is KalVista currently conducting for its sebetralstat treatment?
KalVista is conducting the Phase 3 KONFIDENT clinical trial for sebetralstat, aimed at treating acute HAE attacks.
What was presented regarding the efficacy of sebetralstat at the conference?
Data showed that sebetralstat rapidly inhibits the kallikrein kinin system in patients with HAE, demonstrating its potential as an effective treatment.
What innovative approaches does KalVista's oral Factor XIIa program represent?
The oral Factor XIIa program represents a new generation of therapies that could significantly enhance the treatment of HAE.
